摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

二(D-谷氨酸基-kappaO1)铁水合物(1:1) | 299-29-6

中文名称
二(D-谷氨酸基-kappaO1)铁水合物(1:1)
中文别名
葡萄糖酸亚铁水合物
英文名称
Ferrous gluconate hydrate
英文别名
iron;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid;hydrate
二(D-谷氨酸基-kappaO1)铁水合物(1:1)化学式
CAS
299-29-6;699014-53-4
化学式
C12H26FeO15
mdl
——
分子量
466.17
InChiKey
HLBWMQJLOGMNBR-XRDLMGPZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    0.79[at 20℃]
  • 溶解度:
    自由但缓慢地溶于水,形成绿棕色溶液,更易溶于热水,几乎不溶于乙醇(96%)。
  • LogP:
    -2.6 at 25℃
  • 物理描述:
    DryPowder; PelletsLargeCrystals
  • 颜色/状态:
    The color of /ferrous gluconate/ solution depends on pH; they are light yellow at pH 2, brown at pH 4.5, and green at pH 7. The iron rapidly oxidizes at higher pH.
  • 稳定性/保质期:

    Aqueous solutions are stabilized by the addition of glucose.

  • 分解:
    When heated to decomposition it emits acrid smoke and irritating fumes

计算性质

  • 辛醇/水分配系数(LogP):
    -7.81
  • 重原子数:
    28
  • 可旋转键数:
    10
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    278
  • 氢给体数:
    13
  • 氢受体数:
    15

ADMET

毒理性
  • 肝毒性
典型的口服剂替代剂量并未被确凿地与治疗期间血清酶平升高或特异质、急性临床明显的肝损伤联系起来。相比之下,无论是故意还是意外,口服过量的情况都会导致肝损伤,这主要是中毒的一个组成部分。中毒最常见于幼儿(1至3岁),他们摄入了为成人开具的片。在摄入3克或更多的硫酸亚铁(大约10片,或约650毫克元素)后会发生毒性反应,有毒平是每公斤超过60毫克的元素,而致命平则是每公斤超过180毫克。典型的症状序列是在摄入后1到3小时内出现恶心、呕吐和腹痛,随后是腹泻、虚弱、易怒、嗜睡和昏迷。呕吐物中可能带有血丝或出现明显的呕血。腹泻通常是液体状且颜色较深(由于而不是血液)。在更高剂量下,这一初始阶段会迅速继以苍白、低血压和休克。上消化道和下消化道都可能出血,早期变化包括代谢性酸中毒和凝血病。在某些情况下,症状出现几小时后会有所改善,但随后可能会突然出现血流动力学崩溃、心源性休克和严重酸中毒,这可能是致命的。早期的干预(包括洗胃、补液和螯合)似乎可以改善损伤的过程。肝毒性通常在24小时后出现,成年人的发生率可能高于儿童。严重的肝毒性,伴有黄疸和明显的转酶升高(ALT和AST超过正常上限的25倍),通常仅在较大剂量过量和较高的初始血清平(>1000微克/分升)时发生。黄疸最初较轻,而凝血酶原时间(或INR)延长和酸中毒则较早出现(案例1)。中毒导致死亡的通常原因是心脏骤停,但已有因肝衰竭死亡以及紧急肝移植治疗中毒的报道。有趣的是,急性性肝毒性的肝脏组织学发现是出血性、亚大块坏死,主要位于门脉周围(第1区),这是直接肝毒素的特征,这些毒素不需要肝脏代谢就能产生毒性。在更严重的毒性情况下,损伤是大规模的且波及整个肝叶。
Typical replacement doses of oral iron have not been linked convincingly to serum enzyme elevations during therapy or to idiosyncratic, acute clinically apparent liver injury. In contrast, overdoses of oral iron, whether intentional or accidental, can cause liver injury, largely as a component of iron poisoning. Iron poisoning occurs most common in toddlers (1 to 3 years old) who ingest iron tablets prescribed for adults. Toxicity occurs after ingestion of 3 grams or more of ferrous sulfate (approximately 10 tablets, or ~650 mg of elemental iron), with toxic levels being more than 60 mg/kg of elemental iron and fatal levels more than 180 mg/kg. The typical sequence of events is appearance of nausea, vomiting and abdominal pain within 1 to 3 hours of the ingestion, followed by diarrhea, weakness, irritability, lethargy and stupor. Vomitus may be blood streaked or frank hematemesis. The diarrhea is generally fluid and dark (as a result of iron rather than blood). With higher doses, this initial phase is rapidly followed by pallor, hypotension and shock. Both upper and lower gastrointestinal bleeding can occur and early changes include metabolic acidosis and coagulopathy. In some instances, there is an improvement after a few hours of symptoms which can then be followed by sudden hemodynamic collapse, cardiogenic shock and severe acidosis that may be fatal. Early intervention (with gastric lavage, fluid replacement and iron chelation) appears to ameliorate the course of injury. Liver toxicity generally arises after 24 hours and may be more common in adults than children. Severe liver toxicity, with jaundice and marked aminotransferase elevations (ALT and AST greater than 25 times ULN), generally occurs only with larger overdoses and high initial serum iron levels (>1000 μg/dL). Jaundice is initially mild, while prolongation of the prothrombin time (or INR) and acidosis arise early (Case 1). The usual cause of death from iron poisoning is cardiac arrest, but deaths from hepatic failure as well as emergency liver transplantation for iron poisoning have been reported. Interestingly, the hepatic histological findings of acute iron hepatotoxicity are those of hemorrhagic, submassive necrosis which is predominantly peri-portal (zone 1), a finding typical of direct hepatotoxins that do not require hepatic metabolism for their toxicity. With more severe toxicity, the injury is massive and pan-lobular.
来源:LiverTox
毒理性
  • 相互作用
研究了静脉属补充剂对水杨酸致畸性的影响。在大鼠怀孕的第8、9和10天,分别给予葡萄糖酸亚铁(16 mg/kg)、硫酸锰(10 mg/kg)、硫酸铜(6 mg/kg)或去离子进行腹腔注射。水杨酸钠(250或300 mg/kg)或去离子水杨酸盐处理后1小时,即怀孕第9天通过口服给药。显著增强了水杨酸的致畸效应,增强了水杨酸的效果,但程度不如,而水杨酸的致畸性几乎没有影响。水杨酸处理后6小时,显著增加了胚胎和母体血浆中的总水杨酸浓度。未检测到对血浆蛋白结合水杨酸的干扰。研究了可能的水杨酸-属交互作用对后代的产后影响,在动物怀孕的第8、9和10天给予125 mg/kg阿司匹林口服和16 mg/kg葡萄糖酸亚铁腹腔注射,40天后,与对照相比,阿司匹林-阿司匹林组的探索活动增加和平均体重增加,但只有在阿司匹林共同暴露的动物中迷宫学习能力受损。静脉属盐治疗增强水杨酸的先天和产后效应表明,母体循环中存在水杨酸-属交互作用,并提示螯合作用可能是水杨酸致畸作用的一种机制。
The effects of parenteral metal supplements of salicylate teratogenicity were studied in rats. Ferrous gluconate (16 mg/kg), manganous sulfate (10 mg/kg), cuprous sulfate (6 mg/kg), or deionized water were given ip on days 8, 9, and 10 of gestation. Sodium salicylate (250 or 300 mg/kg) or deionized water was administered /orally/ on day 9, 1 hr after the metal-salt treatment. Mn significantly enhanced the teratogenic effect of salicylate, Fe potentiated the salicylate effect but to a lesser extent than Mn, and Cu has little or no effect on salicylate teratogenicity. Mn and Fe significantly increased total salicylate concentration in both embryos and maternal plasma at 6 hr after salicylate treatment. No interference with plasma protein binding of salicylate could be detected. Postnatal effects of possible salicylate-mental interactions were studied in 40 day old offspring of animals treated with 125 mg/kg aspirin /orally/ and 16 mg/kg ferrous gluconate ip on days 8, 9, and 10. Increased exploratory activity and mean body weight were observed in both the aspirin-Fe and aspirin groups relative to vehicle controls, but maze learning was impaired only in animals exposed to both aspirin and Fe. The potentiation of the pre- and postnatal effects of salicylate by parenteral mental-salt treatment implies a salicylate-mental interaction in the maternal circulation and suggests chelation as a mechanism of the teratogenic action of salicylate.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
研究了不同剂量吸收的影响。11名有回肠造口术的患者(平均年龄55岁,标准差9岁)在3个不同的测试日中,摄入了含12毫克(66Zn和67Zn)和3毫克(65Cu)的稳定同位素标记的溶液,同时摄入0、100或400毫克的(作为硫酸亚铁)。随后,他们静脉注射了1毫克的70Zn。患者在24小时内收集回肠造口液,并在7天内收集尿液。通过尿液中同位素的排泄来计算的状态和真实吸收。通过回肠造口液中口服给予的同位素的排泄来计算表观吸收。在3种剂量下,的状态没有显著差异。在没有的情况下,的吸收显著高于同时摄入100或400毫克的情况(分别为44%±22%,26%±14%和23%±6%,P<0.05),而在100毫克和400毫克铁剂量下,锌的吸收没有显著差异。在0、100和400毫克铁存在下,表观铜吸收分别为48%±14%,54%±26%和53%±7%,且这3种剂量之间没有显著差异。
...The interaction between different amounts of administered iron and the absorption of zinc and copper in humans /was investigated/. Eleven subjects with an ileostomy (mean (+/- SD) age: 55 +/- 9 yr) ingested a stable isotope labeled zinc and copper solution containing 12 mg Zn ((66)Zn and (67)Zn) and 3 mg Cu ((65)Cu) in the presence of 0, 100, or 400 mg Fe as ferrous gluconate on 3 respective test days. Subsequently, 1 mg (70)Zn was injected iv. Subjects collected ileostomy effluent and urine for 24 hr and 7 days, respectively. Zinc status and true zinc absorption were calculated from the urinary excretion of the zinc isotopes. Apparent copper absorption was calculated from ileostomy effluent excretion of the orally administered copper isotopes. Zinc status did not differ significantly between the 3 iron doses. Mean (+/- SEM) zinc absorption was significantly higher in the absence of iron than with the concomitant ingestion of 100 or 400 mg Fe (44 +/- 22% compared with 26 +/- 14% and 23 +/- 6%, respectively; P<0.05), whereas zinc absorption did not differ significantly between the 100- and 400-mg Fe doses. Apparent copper absorption was 48 +/- 14%, 54 +/- 26%, and 53 +/- 7% in the presence of 0, 100, and 400 mg Fe, respectively, and did not differ significantly between the 3 iron doses.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
既然体外实验已经排除了硫酸亚铁(Fe-葡萄糖酸)和氯化氢-L-天冬氨酸(MAH)在溶液中的相互作用,那么目前的体内研究似乎是合理的。动物研究:将大鼠分别饲养在含有充足(Mg)和(Fe)以及缺乏的饮食中。Fe-葡萄糖酸的胃内给药在3小时后显著提高了血浆平,无论是单独给药还是与MAH联合给药(导致高血症)。当强化饮食提供给/缺乏的动物时,也得到了相同的结果。人体研究:Fe-葡萄糖酸(每天2次,每次50毫克,口服)与MAH(每天2次,每次7.5毫摩尔,口服)的组合对健康志愿者来说是耐受性良好的。单次剂量实验显示,Fe-葡萄糖酸单独使用以及与MAH联合使用在3小时内提高了血浆平,效果相同。两组中度贫血的孕妇分别接受Fe-葡萄糖酸(门诊患者)或其与MAH的组合(至少因为早产而暂时住院)。治疗耐受性良好。血红蛋白平在怀孕期间没有进一步下降,这是在没有补充剂的情况下预期的,从而表明两组研究中的电解质都具有治疗可用性。妊娠期间经常观察到孕酮引起的便秘;因此,接受Fe-葡萄糖酸加MAH的50%女性报告的通便作用(与Fe-葡萄糖酸组的33%相比)可以被视为理想的效果。结论是,当两种电解质一起口服给药时,MAH不会干扰Fe-葡萄糖酸的肠内吸收。将两种电解质一起服用,而不是像现在推荐的那样分开2到3小时,意味着更简单的剂量方案,可能改善依从性。
Since in vitro experiments had excluded interactions between Fe-gluconate (Fe-gluc) and magnesium-L-aspartate hydrochloride (MAH) in aqueous solutions the present in vivo studies seemed to be justified. Animal studies: Rats were kept on magnesium-(Mg)- and iron-(Fe)- sufficient and deficient diets. The intragastral administration of Fe-gluc significantly increased plasma Fe after 3 h, either given alone, or in combination with MAH (inducing hypermagnesemia). Same results were obtained when fortified diets were offered to Fe/Mg-deficient animals. Human studies: The combination of Fe-gluc (2 x 50 mg Fe per day, per os) plus MAH (2 x 7.5 mmol Mg per day, p.o.) was well tolerated by healthy volunteers. Single dose experiments revealed that Fe-gluc alone and in combination with MAH increased plasma Fe levels during 3 h to the same extent. Two groups of pregnant women with moderately reduced hemoglobin levels either received Fe-gluc (out-patients) or its combination with MAH (at least temporarily hospitalised because of preterm labor). Treatments were well tolerated. Hemoglobin levels did not further decrease, as expected without Fe supplements, during the course of pregnancy, thus indicating the therapeutic availability of the electrolytes in both study groups. Progesterone-induced constipation is frequently observed during pregnancy; hence stool softening reported by 50% of the women receiving Fe-gluc plus MAH (versus 33% in the Fe-gluc group) can be regarded as desirable effect. It is concluded that MAH does not interfere with the enteral absorption of Fe-gluc when both electrolytes are orally administered together. Taking both electrolytes together instead of 2 to 3 h apart from each other, as actually recommended, means a less complicated dosage regimen and probably improves compliance.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
硫酸亚铁(Fesofor;I)325毫克或葡萄糖酸亚铁(II)600毫克对甲基多巴(Aldomet;III)500毫克片剂吸收、代谢和血压控制的影响在12名正常志愿者(平均年龄,27.6岁)或5名高血压患者(平均年龄,64.8岁)中进行评估,这些患者至少已经服用III一年。当I与III一起服用时,III以游离III形式排出的比例平均下降了49.5%对21.1%,以III硫酸盐形式排出的比例平均显著增加,37.8%对65.8%,III吸收的百分比下降,29.1%对7.88%。这些因素导致游离III排出的量减少了88%。为了确定不含硫酸制剂的效果,研究用II重复进行,结果相同。在高血压患者中,4名患者的收缩压和舒张压均升高,停用I后所有患者的血压均下降。其中3名患者的血压升高幅度较大。
The effect of ferrous sulfate (Fesofor; I) 325 mg or ferrous gluconate (II) 600 mg on methyldopa (Aldomet; III) 500 mg tablet absorption, metabolism and blood pressure control was evaluated in 12 normal volunteers (mean age, 27.6 yr) or 5 hypertensive patients (mean age, 64.8 yr) who had been receiving III for at least one year. When I was taken with III there was a mean decrease in the proportion of III excreted as free III, 49.5% versus 21.1%, a significant mean increase in the proportion excreted as III sulfate, 37.8% versus 65.8%, and a decrease in the percentage of III absorbed, 29.1% versus 7.88%. These factors resulted in an 88% reduction in the quantity of free III excreted. To determine the effect of an iron preparation without sulfate, the study was repeated with II with the same results. In the hypertensive patients, there was an increase in both systolic and diastolic blood pressure in 4 patients and a decrease in blood pressure in all patients after I was discontinued. The increases in blood pressure were substantial in 3 of the patients.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
这项工作中,研究了一种用于食品强化的以甘酸稳定的葡萄糖酸亚铁化合物(SFG)的生物利用度和大鼠急性口服毒性。分别采用预防方法和Wilcoxon方法进行了研究。在前期研究中,SFG被均匀地添加到低含量的基础饮食中,最终浓度为20.1 +/- 2.4 mg Fe/kg饮食。在实验室以类似方式准备了两种对照饮食:一种使用硫酸亚铁作为强化源的参考标准饮食(19.0 +/- 2.1 mg Fe/kg饮食),另一种是没有添加的控制饮食(9.3 +/- 1.4 mg Fe/kg饮食)。这些饮食被作为唯一的固体食物来源,给予三组断奶大鼠,持续23天。SFG的生物利用度是通过治疗期间血红蛋白中吸收的质量与每只动物的总摄入量之间的关系来计算的。这个参数对于SFG来说是36.6 +/- 6.2%,而对于硫酸亚铁来说得到了35.4 +/- 8.0%的值。
The iron bioavailability and acute oral toxicity in rats of a ferrous gluconate compound stabilized with glycine (SFG), designed for food fortification, was studied in this work by means of the prophylactic method and the Wilcoxon method, respectively. For the former studies, SFG was homogeneously added to a basal diet of low iron content, reaching a final iron concentration of 20.1 +/- 2.4 mg Fe/kg diet. A reference standard diet using ferrous sulfate as an iron-fortifying source (19.0 +/- 2.1 mg Fe/kg diet) and a control diet without iron additions (9.3 +/- 1.4 mg Fe/kg diet) were prepared in the laboratory in a similar way. These diets were administered to three different groups of weaning rats during 23 d as the only type of solid nourishment. The iron bioavailability of SFG was calculated as the relationship between the mass of iron incorporated into hemoglobin during the treatment and the total iron intake per animal. This parameter resulted in 36.6 +/- 6.2% for SFG, whereas a value of 35.4 +/- 8.0% was obtained for ferrous sulfate.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
的胃肠道吸收是足够的,从硫酸亚铁富马酸盐、葡萄糖酸盐、琥珀酸盐、谷酸盐和乳酸盐中吸收实质上是相等的。
Gastrointestinal absorption of iron is adequate and essentially equal from...ferrous...sulfate, fumarate, gluconate, succinate, glutamate, and lactate.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 安全说明:
    S22,S24/25
  • WGK Germany:
    2
  • 危险品运输编号:
    50kgs
  • RTECS号:
    LZ5150000
  • 海关编码:
    2918160000
  • 危险性防范说明:
    P501,P270,P264,P301+P312+P330
  • 危险性描述:
    H302

制备方法与用途

食品添加剂最大允许使用量及残留量标准 葡萄糖酸亚铁[矿物质类] 允许使用该种添加剂的食品中文名称及其功能 化学性质
  • 黄灰色或浅绿黄色细粉或颗粒
  • 易溶于(10g/100ml温),几乎不溶于乙醇
  • 5%溶液对石蕊呈酸性,溶液加葡萄糖可使其稳定
  • 稍有焦糖似的气味
用途 生产方法 类别与毒性分级
  • 有毒物质
  • 毒性分级:中毒
  • 急性毒性:口服-大鼠 LD50 2237 毫克/公斤;口服-小鼠 LD50: 3950 毫克/公斤
燃烧特性与储运
  • 可燃,燃烧时分解有毒氮氧化物和氧化物气体
  • 库房低温、通风、干燥储存
  • 灭火剂:二氧化碳、泡沫、沙土
职业标准
  • TWA 1 毫克()/立方米